Extended Data Fig. 1: Schedule of infection, vaccination, and sample collection.
Fifty-three study participants with prior SARS-CoV-2 infection as documented by seropositivity to S and N proteins and participant P845 who was seronegative prior to vaccination received either BNT162 or mRNA-1273 1st dose (closed circle), 2nd dose (closed triangle), and booster (3rd) dose (closed square) on the days after symptom onset as shown. Persons with mild or moderate COVID-19 are shown in magenta, persons with severe COVID-19 in black. Duration of hospitalization in persons with severe COVID-19 is shown in purple. PBMC were obtained at exam visits convalescence (E00, n = 54), late convalescence (E00.5, n = 16), pre-dose 1 (E01, n = 34), post-dose 1 (E02, n = 52), post-dose 2 (E03, n = 53), pre-boost (E04, n = 7), and post-boost (E05, n = 44). 33 persons had samples at E00, E01 and E03, 31 had samples at E00, E01, E02, and E03, and 26 had samples at all of E00, E01, E02, E03, and E05. Three participants were observed to have breakthrough COVID-19 infection based on boosting of anti-nucleocapsid antibody levels at visit E05 (P545, P664, P669), indicated in orange. All participants received primary vaccination but not all received a booster dose.
